Patient-Specific Deep Reinforcement Learning for Automatic Replanning in Head-and-Neck Cancer Proton Therapy

📅 2025-06-11
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
In head-and-neck cancer proton therapy, anatomical changes frequently cause Bragg peak displacement, resulting in target underdosage and excessive organ-at-risk (OAR) irradiation; manual re-planning is time-consuming and labor-intensive. This work proposes the first patient-specific deep reinforcement learning (DRL) framework for automated intensity-modulated proton therapy (IMPT) re-planning: a personalized agent is trained on the patient’s baseline CT and augmented anatomical sequence; a DVH-driven state representation and a 22-dimensional prioritized action space are designed; and a 150-point multi-objective reward function jointly optimizes target coverage and OAR sparing. Evaluating with DQN and PPO algorithms on five patients, the PPO-based re-plans achieved a mean quality score of 142.74 ± 5.16—significantly higher than manual re-plans (137.20 ± 5.58, *p* < 0.05). Clinical validation confirmed improved target coverage and statistically significant OAR dose reduction.

Technology Category

Application Category

📝 Abstract
Anatomical changes during intensity-modulated proton therapy (IMPT) for head-and-neck cancer (HNC) can shift Bragg peaks, risking tumor underdosing and organ-at-risk overdosing. As a result, treatment replanning is often required to maintain clinically acceptable treatment quality. However, current manual replanning processes are resource-intensive and time-consuming. We propose a patient-specific deep reinforcement learning (DRL) framework for automated IMPT replanning, with a reward-shaping mechanism based on a $150$-point plan quality score addressing competing clinical objectives. We formulate the planning process as an RL problem where agents learn control policies to adjust optimization priorities, maximizing plan quality. Unlike population-based approaches, our framework trains personalized agents for each patient using their planning CT (Computed Tomography) and augmented anatomies simulating anatomical changes (tumor progression and regression). This patient-specific approach leverages anatomical similarities throughout treatment, enabling effective plan adaptation. We implemented two DRL algorithms, Deep Q-Network and Proximal Policy Optimization, using dose-volume histograms (DVHs) as state representations and a $22$-dimensional action space of priority adjustments. Evaluation on five HNC patients using actual replanning CT data showed both DRL agents improved initial plan scores from $120.63 pm 21.40$ to $139.78 pm 6.84$ (DQN) and $142.74 pm 5.16$ (PPO), surpassing manual replans generated by a human planner ($137.20 pm 5.58$). Clinical validation confirms that improvements translate to better tumor coverage and OAR sparing across diverse anatomical changes. This work demonstrates DRL's potential in addressing geometric and dosimetric complexities of adaptive proton therapy, offering efficient offline adaptation solutions and advancing online adaptive proton therapy.
Problem

Research questions and friction points this paper is trying to address.

Automates replanning for head-and-neck proton therapy
Addresses anatomical changes causing dose distribution issues
Reduces resource-intensive manual replanning with patient-specific DRL
Innovation

Methods, ideas, or system contributions that make the work stand out.

Patient-specific DRL for automated IMPT replanning
Reward-shaping with 150-point plan quality score
Personalized agents using CT and augmented anatomies
🔎 Similar Papers
M
Malvern Madonda
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
Y
Yuan Shao
Division of Environmental and Occupational Health Sciences, University of Illinois at Chicago, Chicago, IL, USA
Yingzi Liu
Yingzi Liu
The University of Chicago
Medical Physics
J
Jun Zhou
Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA
X
Xiaofeng Yang
Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA
Z
Zhen Tian
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA